In 2005, the U.S. Department of Defense (DoD) Chemical Biological Medical Systems – Medical Identification and Treatment Systems (CMBS-MITS), building on the work of Army scientists, awarded a contract to DynPort for further advance development of human plasma-derived BioScavenger as a pre-exposure therapeutic, or prophylactic, against chemical nerve agents.